Badi E. Osta
Experienced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Badi E. Osta

Oncology
Emory health
Emory Winship Cancer Institute
1365 Clifton Road Northeast, 
Atlanta, GA 
28 Years of Experience
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Emory health
Emory Winship Cancer Institute
1365 Clifton Road Northeast, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Badi Osta is an Oncologist in Atlanta, Georgia. Dr. Osta has been practicing medicine for over 28 years and is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

His clinical research consists of co-authoring 12 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles and participated in 7 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Graduate Institution
American University Of Beirut, Lebanon, 1998.0
Residency
Good Samaritan Hospital - OH
Specialties
Oncology
Licenses
Internal Medicine in GA
Board Certifications
American Board Of Internal Medicine, 2016
Fellowships
Medical College of Georgia
MD Anderson Cancer Center
Languages Spoken
English
Arabic
French
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, Atlanta, GA 30322
Call: 404-778-1900

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2026
Intervention Type: Biological, Drug
Study Drugs: Docetaxel, Pembrolizumab, Ramucirumab
Study Phase: Phase 2
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Sotorasib
Study Phase: Phase 2
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors
Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors
Enrollment Status: Completed
Publish Date: October 08, 2024
Intervention Type: Biological, Drug
Study Drugs: VEGFR/PDGFR Dual Kinase Inhibitor X-82, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
View 7 Less Clinical Trials

12 Total Publications

What is on the Horizon Beyond Platinum and Immunotherapy for Patients With Advanced Non-Small Cell Lung Cancer Without Actionable Genomic Aberrations?
What is on the Horizon Beyond Platinum and Immunotherapy for Patients With Advanced Non-Small Cell Lung Cancer Without Actionable Genomic Aberrations?
Journal: JCO oncology practice
Published: December 19, 2025
View All 12 Publications
Similar Doctors
Suresh S. Ramalingam
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Suresh S. Ramalingam
Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Suresh S. Ramalingam
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (1.0 miles away)
404-778-1900
Experience:
34+ years
Languages Spoken:
English, Tamil
See accepted insurances
Offers Telehealth

Suresh Ramalingam is an Oncologist in Atlanta, Georgia. Dr. Ramalingam has been practicing medicine for over 34 years and is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Ticiana Leal
Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Ticiana Leal
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (1.0 miles away)
404-778-1900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ticiana Leal is an Oncologist in Atlanta, Georgia. Dr. Leal is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Endoscopy, and Colonoscopy.

Conor E. Steuer
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Conor E. Steuer
Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Conor E. Steuer
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (1.0 miles away)
404-778-1900
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Conor Steuer is an Oncologist in Atlanta, Georgia. Dr. Steuer has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Tissue Biopsy, and Gastrostomy.

VIEW MORE NON-SMALL CELL LUNG CANCER (NSCLC) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Osta's expertise for a condition
ConditionClose
        • Experienced
        • ALK-Positive Non-Small Cell Lung Cancer
          Dr. Osta is
          Experienced
          . Learn about ALK-Positive Non-Small Cell Lung Cancer.
          See more ALK-Positive Non-Small Cell Lung Cancer experts
        • EGFR Positive Lung Cancer
          Dr. Osta is
          Experienced
          . Learn about EGFR Positive Lung Cancer.
          See more EGFR Positive Lung Cancer experts
        • Large-Cell Lung Carcinoma
          Dr. Osta is
          Experienced
          . Learn about Large-Cell Lung Carcinoma.
          See more Large-Cell Lung Carcinoma experts
        • Lung Adenocarcinoma
          Dr. Osta is
          Experienced
          . Learn about Lung Adenocarcinoma.
          See more Lung Adenocarcinoma experts
        • Lung Cancer
          Dr. Osta is
          Experienced
          . Learn about Lung Cancer.
          See more Lung Cancer experts
        • Non-Small Cell Lung Cancer (NSCLC)
          Dr. Osta is
          Experienced
          . Learn about Non-Small Cell Lung Cancer (NSCLC).
          See more Non-Small Cell Lung Cancer (NSCLC) experts
        View All 9 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile
        For Patients
        • Our Story
        • How MediFind Works
        • Conditions A-Z
        • Doctor Directory
        • Symptoms Directory
        • Procedures Directory
        • Treatment Directory
        • Drug Directory
        • Infusion Center Finder
        • FAQ
        • Contact Us
        For Providers and Practices
        • Claim Your Profile
        • Newsroom
        Business Solutions
        • Provider
        • Network Solutions
        Additional Resources
        • Consumer Health Data Privacy Policy
        • Privacy Policy
        • Terms of Use
        • Advertising Policy
        • Content Policy
        Subscribe to our newsletter

        Sign up to stay informed about MediFind and get wellness sent your way.

        Close

          By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

          Bullet PinMediFind
          Follow us on
          This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
          © 2026 All Rights Reserved

          Request an Appointment

          If you are experiencing a medical emergency, call 9-1-1.

          Once you submit your request, MediFind will reach out to the provider’s office to help schedule your appointment. Note that this is not a confirmed booking. You’ll receive a status update via email within 1–2 business days.

          Patient Details

          This information is for the patient who will be seen at the appointment.

              Close

              Returning patient? Use your address on file with the provider.

              Insurance Details

              Please provide information of the primary insurance holder as the practice may require this information to schedule.

              Insurance Provider *
              Insurance ProviderClose

              Appointments Details

              Let’s get more information about your appointment.

                      0 / 1000
                      By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.